Achieve Life Sciences, Inc. ACHV
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $15.00 (+119.6% upside)
Key Stats
- Today's Range
- $6.57 – $7.29
- 50-Day Range
- $6.22 – $8.64
- 52-Week Range
- $2.62 – $8.64
- Volume
- 1.38 million shs
- Average Volume
- 1.35 million shs
- Market Cap
- $741.31 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.13%
- Days to Cover
- 1.43
About Achieve Life Sciences, Inc.
Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
Related Stocks
Compare head-to-head: ACHV vs IDXX·ACHV vs LNTH·ACHV vs CLDX·ACHV vs NTLA
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.